Patent Bill May Get Stuck In “Second Window” Review; Amgen Urges Pilot
Executive Summary
The fate of proposed legislative reforms to the patent system may rest on discussions between the pharma and tech industries
You may also be interested in...
Amended Patent Bill Limits Opportunities For “Second Window” Review
A new version of patent reform legislation would allow a patent to be challenged anytime during its life, but set stricter requirements for requesting a review after the first year
Amended Patent Bill Limits Opportunities For “Second Window” Review
A new version of patent reform legislation would allow a patent to be challenged anytime during its life, but set stricter requirements for requesting a review after the first year
Patent Reform Bill Gets Cool Reception From Rx Industry; Damage Cap Is Worry
A new patent reform bill introduced in Congress is likely to undergo revisions in the face of criticism from the pharmaceutical industry